(Q37086022)

18 August 2017

1 reference

title

mTOR pathway in renal cell carcinoma (English)

1 reference

18 August 2017

Sara C Hanna

1

1 reference

PubMed ID

18279068

18 August 2017

Samuel A Heathcote

series ordinal

2

1 reference

PubMed ID

18279068

18 August 2017

William Y Kim

series ordinal

3

1 reference

18 August 2017

1 February 2008

1 reference

Expert Review of Anticancer Therapy

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

283-292

1 reference

18 August 2017

2

1 reference

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Exogenous amino acids regulate trophectoderm differentiation in the mouse blastocyst through an mTOR-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Regulation of cellular growth by the Drosophila target of rapamycin dTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

A nutrient sensor mechanism controls Drosophila growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

mTOR and cancer: reason for dancing at the crossroads?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Synthesis of the translational apparatus is regulated at the translational level

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

TSC2: filling the GAP in the mTOR signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Rheb binds and regulates the mTOR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

The LKB1 tumor suppressor negatively regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

HIF-1 and mechanisms of hypoxia sensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

A cross sectional study of renal involvement in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Loss of tumor suppressor protein PTEN during renal carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Mutations in the ras protooncogenes are rare events in renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Role of the Ras-association domain family 1 tumor suppressor gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Invasive growth: a MET-driven genetic programme for cancer and stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.283

21 January 2018

Identifiers

DOI

10.1586/14737140.8.2.283

1 reference

18 August 2017

1 reference

PubMed ID

18279068